Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

β2-Adrenergic Receptor Agonists and cAMP Arrest Human Cultured Airway Smooth Muscle Cells in the G1 Phase of the Cell Cycle: Role of Proteasome Degradation of Cyclin D1

Alastair G. Stewart, Trudi Harris, Darren J. Fernandes, Leslie C. Schachte, Valentina Koutsoubos, Elizabeth Guida, Claire E. Ravenhall, Peter Vadiveloo and John W. Wilson
Molecular Pharmacology November 1999, 56 (5) 1079-1086; DOI: https://doi.org/10.1124/mol.56.5.1079
Alastair G. Stewart
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trudi Harris
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darren J. Fernandes
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie C. Schachte
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Koutsoubos
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Guida
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire E. Ravenhall
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Vadiveloo
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Wilson
1 2 3
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Hyperplasia of airway smooth muscle (ASM) contributes to the airway hyperresponsiveness that characterizes asthma. We have investigated the relationship between cAMP-induced growth arrest of ASM cells and thrombin-stimulated, extracellular-regulated protein kinase (ERK) activity, cyclin D1, and the restriction protein retinoblastoma. The β2-adrenergic receptor agonist albuterol (100 nM) inhibited DNA synthesis after incubation with ASM for periods as brief as 1 h when these coincided with the timing of the restriction point. Inhibition of thrombin-stimulated DNA synthesis by albuterol (1–100 nM), 8-bromo-cAMP (300 μM), or prostaglandin E2(1 μM) was accompanied by a reduction in cyclin D1 protein levels. The ERK kinase inhibitor PD98059 (3–30 μM) attenuated thrombin-stimulated ERK phosphorylation and activity and the increase in cyclin D1 protein levels, as did albuterol (1–100 nM) or 8-bromo-cAMP (300 μM). In contrast, neither albuterol (100 nM) nor PD98059 (30 μM) reduced cyclin D1 mRNA levels between 4 and 20 h after thrombin addition, which suggests that elevation of cAMP regulates cyclin D1 by a post transcriptional mechanism. The proteasome inhibitor MG132 (30 and 100 nM) and the calpain I inhibitorN-acetyl-Leu-Leu-leucinal (10 μM) attenuated the reduction in thrombin-stimulated cyclin D1 levels in ASM exposed to albuterol (100 nM), 8-bromo-cAMP (300 μM), or the phosphodiesterase inhibitor isobutylmethylxanthine (100 μM). Thus, the cAMP-induced arrest of ASM in the G1 phase of the cell cycle is associated with a proteasomal degradation of cyclin D1 protein and a reduced protein retinoblastoma phosphorylation that prevents passage through the restriction point.

Footnotes

    • Received April 19, 1999.
    • Accepted July 30, 1999.
  • Send reprint requests to: Alastair G. Stewart, Ph.D., Department of Pharmacology, University of Melbourne, Parkville, Victoria 3052, Australia. E-mail:a.stewart{at}pharmacology.unimelb.edu.au

  • This work was supported in part by National Health Medical Research Council (Australia) and GlaxoWellcome (Uxbridge, UK).

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 56 (5)
Molecular Pharmacology
Vol. 56, Issue 5
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
β2-Adrenergic Receptor Agonists and cAMP Arrest Human Cultured Airway Smooth Muscle Cells in the G1 Phase of the Cell Cycle: Role of Proteasome Degradation of Cyclin D1
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

β2-Adrenergic Receptor Agonists and cAMP Arrest Human Cultured Airway Smooth Muscle Cells in the G1 Phase of the Cell Cycle: Role of Proteasome Degradation of Cyclin D1

Alastair G. Stewart, Trudi Harris, Darren J. Fernandes, Leslie C. Schachte, Valentina Koutsoubos, Elizabeth Guida, Claire E. Ravenhall, Peter Vadiveloo and John W. Wilson
Molecular Pharmacology November 1, 1999, 56 (5) 1079-1086; DOI: https://doi.org/10.1124/mol.56.5.1079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

β2-Adrenergic Receptor Agonists and cAMP Arrest Human Cultured Airway Smooth Muscle Cells in the G1 Phase of the Cell Cycle: Role of Proteasome Degradation of Cyclin D1

Alastair G. Stewart, Trudi Harris, Darren J. Fernandes, Leslie C. Schachte, Valentina Koutsoubos, Elizabeth Guida, Claire E. Ravenhall, Peter Vadiveloo and John W. Wilson
Molecular Pharmacology November 1, 1999, 56 (5) 1079-1086; DOI: https://doi.org/10.1124/mol.56.5.1079
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics